OTCMKTS:BIXT Bioxytran (BIXT) Stock Price, News & Analysis $0.02 0.00 (0.00%) As of 09/25/2026 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsNews and TrendsSEC Filings About Bioxytran Stock (OTCMKTS:BIXT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bioxytran alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.02▼$0.09Volume24,000 shsAverage Volume63,636 shsMarket Capitalization$2.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bioxytran, Inc. is a development-stage biotechnology company focused on creating treatments for medical conditions associated with inadequate oxygen delivery to tissues. The company is developing therapies based on a proprietary nanobubble platform designed to transport and deliver oxygen in the body. Bioxytran’s lead development program, BXT-25, is an investigational intravenous product intended to improve oxygenation in patients affected by ischemic stroke. The company has also described potential applications for its technology in other conditions involving tissue oxygen deprivation, although these programs remain subject to research, development and regulatory evaluation. Bioxytran primarily operates as a biotechnology research and development company and does not appear to have an approved commercial product portfolio. Information about the company’s broader geographic operations and current leadership is limited in publicly available sources.AI Generated. May Contain Errors. Read More Bioxytran Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks3rd Percentile Overall ScoreBIXT MarketRank™: Bioxytran scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bioxytran. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioxytran is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioxytran is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.00% of the float of Bioxytran has been sold short.Short Interest Ratio / Days to CoverBioxytran has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bioxytran has recently increased by 100.00%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioxytran does not currently pay a dividend.Dividend GrowthBioxytran does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Bioxytran to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bioxytran insiders have not sold or bought any company stock.Percentage Held by Insiders70.00% of the stock of Bioxytran is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsBioxytran has minimal institutional ownership at this time.Read more about Bioxytran's insider trading history. Receive BIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIXT Stock News HeadlinesBIOXYTRAN, INC.: Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel ...August 11, 2026 | finanznachrichten.deBioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist ...August 11, 2026 | markets.businessinsider.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 28 at 1:00 AM | Behind the Markets (Ad)Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis DrugsAugust 4, 2026 | globenewswire.comBioxytran Announces Publication of Corporate Research Report by Globe Small Cap ResearchJuly 29, 2026 | globenewswire.comBioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25May 29, 2026 | globenewswire.comBioxytran Delays Annual 10-K FilingApril 1, 2026 | tipranks.comBioxytran Raises Capital to Advance Development and CommercializationMarch 20, 2026 | tipranks.comSee More Headlines BIXT Stock Analysis - Frequently Asked Questions How have BIXT shares performed this year? Bioxytran's stock was trading at $0.0753 on January 1st, 2026. Since then, BIXT shares have decreased by 72.0% and is now trading at $0.0211. How were Bioxytran's earnings last quarter? Bioxytran, Inc. (OTCMKTS:BIXT) announced its earnings results on Friday, August, 14th. The company reported ($0.01) earnings per share for the quarter. How do I buy shares of Bioxytran? Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioxytran own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioxytran investors own include AMC Entertainment (AMC), Armata Pharmaceuticals (ARMP), Esports Entertainment Group (GMBL), Genius Group (GNS), Novavax (NVAX) and Karora Resources Inc. (RNX.TO) (RNX). Company Calendar Last Earnings8/14/2026Today9/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:BIXT CIK1445815 Webwww.bioxytraninc.com Phone(617) 454-1199FaxN/AEmployees2Year Founded2008Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.12 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-792.61% Debt Debt-to-Equity RatioN/A Current Ratio0.03 Quick Ratio0.03 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-1.06Miscellaneous Outstanding Shares114,690,000Free Float34,409,000Market Cap$2.42 million OptionableNot Optionable Beta1.88 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (OTCMKTS:BIXT) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioxytran With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
